Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2

Last updated: September 5, 2023
Sponsor: Icahn School of Medicine at Mount Sinai
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alzheimer's Disease

Treatment

Active lighting intervention

Control lighting intervention

Clinical Study ID

NCT05837819
  • Ages > 65
  • All Genders

Study Summary

Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of Alzheimer's disease or related dementia with a Montreal Cognitive Assessment score <25
  • Sleep disturbance with a Pittsburgh Sleep Quality Index score ≥5

Exclusion

Exclusion Criteria:

  • Extensive brain vascular disease, traumatic brain injury, multiple sclerosis, Parkinson's Disease
  • Obstructing cataracts
  • Severe macular degeneration
  • Use of sleep medication
  • Use of oral melatonin
  • untreated moderate to severe sleep apnea
  • Severe restless leg syndrome
  • Blindness

Study Design

Total Participants: 135
Treatment Group(s): 2
Primary Treatment: Active lighting intervention
Phase:
Study Start date:
February 14, 2023
Estimated Completion Date:
December 05, 2025

Study Description

Connect with a study center

  • Icahn School of Medicine at Mount Sinai

    Albany, New York 12204
    United States

    Active - Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York 10029
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.